4
Changes in Ownership
Rapport Therapeutics, Inc. Filed Acc 0000950170-25-074409
Chief Scientific Officer sold 8,500 shares at $9.56 ($81,262)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Bredt David Chief Scientific Officer | 2025-05-15 | Sale 10b5-1 | −8,500 | $9.56 | $81,262 | 452,142 | D |
| Open-market sales · 8,500 sh · avg $9.56 · $81,262 | |||||||
Loading xslF345X05/ownership.xml…